Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves StemCyte’s cord blood stem cell therapy BLA
The approval makes the company the first commercial biotech to receive such a license for this cell therapy type. Derived from the umbilical cord blood of humans, the
The approval makes the company the first commercial biotech to receive such a license for this cell therapy type. Derived from the umbilical cord blood of humans, the
The funding is set to enhance the company’s C1 protein production platform to enable rapid, cost-effective production of mAbs. This initiative focuses on diseases like RSV and malaria,
This partnership aims to address the global obesity epidemic by fast-tracking an innovative therapy that could improve the lives of millions. It includes the progression of LAE102 through
This small interfering ribonucleic acid (RNA)[siRNA] therapy is designed to combat one of the ALS subtypes, FUS-ALS, by reducing FUS protein levels. RAG-21 leverages RNA interference (RNAi) technology
The FDA has set a target action date of 18 April 2025 for its decision. If approved, Dupixent is expected to become the first targeted CSU therapy in
This grant will aid the progression of ASHA-624 towards first-in-human clinical trials. Designed using the company’s PRISM drug design technology, it is a brain-penetrant intra-molecular glue inhibitor of
The BLA is sought for treating NSCLC patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) who have received systemic therapies previously. Concurrently, the companies have
The $0.6m (4m yuan) deal, which will facilitate Lakeside’s entry into the medical logistics sector, is set to contribute an estimated $7m in annual revenues to the integrated
ALT-B4 will be used for developing the subcutaneous formulation ENHERTU. As per the agreement, Daiichi Sankyo will gain global rights to utilise Alteogen’s ALT-B4, a human recombinant hyaluronidase
Situated in Milton Park, near Oxford, the new 30,000ft2 facility is part of NEB’s wholly-owned subsidiary network. The site is designed to offer solutions for ambient molecular biology